SCHEMBL25220159

SCHEMBL25220159

FC(F)(F)c1ccc2ccnn2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 2/20 0.38
MAPK14 Q16539 1/20 0.36
ALDH1A1 P00352 3/20 0.34
TSHR P16473 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
KDM4E B2RXH2 2/20 0.34
SCN5A Q14524 2/20 0.34
HSD17B10 Q99714 1/20 0.34
SLC6A2 P23975 1/20 0.34
SLC6A4 P31645 1/20 0.34
SLC6A3 Q01959 1/20 0.34
OXTR P30559 2/20 0.33
AVPR1A P37288 2/20 0.33
DRD2 P14416 1/20 0.33
DRD4 P21917 1/20 0.33
DRD3 P35462 1/20 0.33
NPC1 O15118 2/20 0.33
EPHX2 P34913 1/20 0.33
MAPK1 P28482 1/20 0.32
POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30645090 0.81 MAPK14 (0.32) KIF11MAPK14ALDH1A1TSHRSMN1; SMN2
SCHEMBL13292357 0.80 SLC6A2 (0.37) KIF11ALDH1A1TSHRKDM4ESLC6A2
SCHEMBL22714880 0.77 MAP4K4 (0.37) SLC6A2SLC6A4SLC6A3DRD2DRD4
SCHEMBL22726507 0.74 CYP19A1 (0.34) SLC6A2SLC6A4SLC6A3DRD2DRD4
SCHEMBL20689977 0.74 NPC1 (0.39) SMN1; SMN2SLC6A2SLC6A4SLC6A3DRD2
SCHEMBL22726510 0.73 SLC6A2 (0.33) SLC6A2SLC6A4SLC6A3DRD2DRD4
SCHEMBL21025977 0.73 DRD2 (0.35) SLC6A2SLC6A4SLC6A3DRD2DRD4
SCHEMBL4224982 0.72 SLC6A2 (0.36) MAPK14SCN5ASLC6A2SLC6A4SLC6A3
SCHEMBL22715105 0.72 SLC6A2 (0.35) KDM4ESLC6A2SLC6A4SLC6A3DRD3
SCHEMBL22726675 0.72 SLC6A2 (0.33) SLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4619402-A1 GPR17 MODULATORS AND USES THEREOF Myrobalan Therapeutics, Inc. (US) 2025-09-24 EP disclosed
CN-119613397-A N-heteroaromatic ring-3-sulfonamide compounds and use thereof for preparing GPR17 receptor inhibitors 迈巴制药(南京)有限公司 2025-03-14 CN disclosed
US-20250066318-A1 HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS PROTHENA BIOSCIENCES INC 2025-02-27 US disclosed
CN-118843626-A Heterocyclic compounds as DYRK1A inhibitors 普罗塞纳生物科学有限公司 2024-10-25 CN disclosed
EP-4444421-A2 HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS Prothena Biosciences Limited (IE) 2024-10-16 EP disclosed
WO-2024104462-A1 GPR17 MODULATORS AND USES THEREOF MYROBALAN THERAPEUTICS NANJING CO. LTD (CN) 2024-05-23 WO disclosed
WO-2023164235-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS AGIOS PHARMACEUTICALS, INC. (US) 2023-08-31 WO disclosed
WO-2023107714-A2 METHODS FOR TREATING NEUROLOGICAL DISORDERS PROTHENA BIOSCIENCES LIMITED (IE) 2023-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250066318-A1 HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS DYRK1A, DYRK2, DYRK1B KIF11 1814/4885MAPK14 371/4885ALDH1A1 3352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.